ROIV — Roivant Sciences Ltd.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1635088 · United Kingdom
Last close
$38.71
Market Cap
$28.05B
52W High
$42.50
52W Low
$19.96
ADV30
7,733,231
Next earnings
2027-02-04
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 35,121,000 31,774,000 -268,049,000 -191,619,000 4,975,824,000 — 4,975,824,000
Jun 2026 1,442,000 1,158,000 -366,385,000 -189,837,000 5,306,493,000 1,248,456,000 384,624,000
Mar 2026 2,520,000 2,200,000 -354,995,000 302,994,000 5,708,687,000 1,419,232,000 416,275,000
Dec 2025 1,999,000 1,299,000 -339,153,000 -265,891,000 5,225,368,000 1,478,270,000 251,144,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-36,388,000
Investing CF
$606,760,000
Financing CF
$-171,307,000
CapEx
$-9,736,000
Dividends Paid
—
Buybacks
$-392,413,000
EPS Diluted TTM
$-0.63
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,164,473,000
Inventory
—
Receivables
$771,627,000
ST Investments
$2,593,626,000
EBIT TTM
$-1,328,582,000
Pretax Income TTM
$-297,181,000
Interest Exp TTM
—
Analysts
11

Yahoo Snapshot (yfinance, live)

Total Revenue
$41,082,000
EBITDA
$-1,322,877,952
Free Cash Flow
$-358,864,864
Enterprise Value
$25,116,303,360
Total Cash
$4,207,586,048
Total Debt
$106,570,000
Shares Out
724,561,460
Trailing EPS
$-0.65
Book Value
$5.55
ROE
-8.5%
ROA
-16.5%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Mar 2026 8,260,000 -1,285,303,000 -299,771,000 5,708,687,000 416,275,000 4,527,370,000 -750,349,000
Mar 2025 29,053,000 -1,113,681,000 -171,981,000 5,436,940,000 249,742,000 4,687,605,000 -839,451,000
Mar 2024 32,713,000 -824,928,000 4,348,926,000 7,222,482,000 773,953,000 5,968,581,000 -765,268,000
Mar 2023 31,530,000 -809,014,000 -1,009,030,000 2,389,604,000 782,017,000 1,157,766,000 -843,393,000

TTM Snapshot

Revenues TTM
$7,532,000
NetIncome TTM
$-266,253,000
OpCashFlow TTM
—
Assets (Latest)
$5,306,493,000
Forward EPS
$-1.61

Max Pain — expiry 2026-12-18

max pain strike: $37.00 · spot: $38.73 · call oi: 21,051 · put oi: 12,829
Expected Move to 2026-12-18: ±$6.88 (17.75%) — implied range $31.85 – $45.60 · ATM straddle on $39.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
INSM INSMED Inc $26.73B $121.86 —
RPRX Royalty Pharma plc $30.58B $68.68 —
UTHR UNITED THERAPEUTICS Corp $24.88B $584.10 —
GMAB GENMAB A/S $31.95B $51.96 —
VTRS Viatris Inc $23.45B $20.45 —

News headlines (Yahoo Finance, 1h cache)

How Trial Wins And Drug Launch Revenue Will Impact Roivant Sciences Stock (ROIV)
2026-11-12 07:14 · Yahoo
Roivant Sciences Ltd (ROIV) (Q2 2026) Earnings Call Highlights: LISRIA Launch Delivers $31 ...
2026-11-10 09:02 · Yahoo
Roivant Sciences (ROIV) Q2 2026 Earnings Call Transcript
2026-11-09 22:13 · Yahoo
Roivant Sciences Q2 Earnings Call Highlights
2026-11-09 17:15 · Yahoo
Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Tops Revenue Estimates
2026-11-09 12:40 · Yahoo
Roivant Sciences (ROIV) Stock Looks Expensive Against Its Book Value
2026-11-05 06:13 · Yahoo
Roivant Soars 8% as Brepocitinib Delivers “Phenomenal Results” in Two Phase 3 Uveitis Trials
2026-10-23 17:25 · Yahoo
Roivant Sciences’ Brepocitinib Delivers Positive Phase III Uveitis Results
2026-10-21 15:04 · Yahoo
Roivant Sciences stock surges on positive uveitis trial data
2026-10-21 13:09 · Yahoo
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
2026-10-21 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.